Santhera Pharmaceuticals Holding AG
SIX:SANN.SW
9.22 (CHF) • At close September 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) CHF.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 103.376 | 7.473 | -1.595 | 15.008 | 75.376 | 31.657 | 22.943 | 19.033 | 4.321 | 2.591 | 1.319 | 3.538 | 3.265 | 20.609 | 1.643 | 0.048 | 9.226 | 0.781 |
| Cost of Revenue
| 3.87 | 3.592 | 3.767 | 10.431 | 5.45 | 4.702 | 4.104 | 3.883 | 1.371 | 0.199 | 0.14 | 0.349 | 0.338 | 0.378 | 0.244 | 0.023 | 0 | 0 |
| Gross Profit
| 99.506 | 3.881 | -5.362 | 4.577 | 69.926 | 26.955 | 18.839 | 15.15 | 2.95 | 2.392 | 1.179 | 3.189 | 2.927 | 20.231 | 1.399 | 0.025 | 9.226 | 0.781 |
| Gross Profit Ratio
| 0.963 | 0.519 | 3.362 | 0.305 | 0.928 | 0.851 | 0.821 | 0.796 | 0.683 | 0.923 | 0.894 | 0.901 | 0.896 | 0.982 | 0.851 | 0.521 | 1 | 1 |
| Reseach & Development Expenses
| 18.674 | 30.536 | 29.715 | 34.228 | 41.244 | 38.24 | 26.561 | 17.675 | 10.453 | 5.695 | 4.709 | 28.724 | 18.125 | 15.69 | 31.536 | 31.467 | 15.526 | 11.018 |
| General & Administrative Expenses
| 21.184 | 14.565 | 12.725 | 12.44 | 19.184 | 15.365 | 14.416 | 9.805 | 8.244 | 4.164 | 3.109 | 4.08 | 10.213 | 10.442 | 13.206 | 10.624 | 2.658 | 3.952 |
| Selling & Marketing Expenses
| 9.782 | 10.857 | 9.332 | 11.474 | 20.096 | 24.884 | 28.522 | 21.051 | 8.356 | 0.574 | 0.926 | 1.841 | 2.076 | 3.452 | 3.752 | 3.484 | 0.649 | 0 |
| SG&A
| 30.331 | 25.422 | 22.057 | 23.914 | 39.28 | 40.249 | 42.938 | 30.856 | 16.6 | 4.738 | 4.035 | 5.921 | 12.289 | 13.894 | 16.958 | 14.108 | 3.307 | 3.952 |
| Other Expenses
| 0 | -0.101 | -0.246 | -0.489 | -0.156 | -0.114 | -0.206 | -0.254 | -0.172 | -0.524 | -0.256 | -0.301 | -0.274 | -0.642 | 72.408 | 0.041 | 23.959 | 15.087 |
| Operating Expenses
| 49.005 | 55.857 | 51.526 | 57.653 | 80.368 | 78.375 | 69.293 | 48.277 | 26.881 | 9.909 | 8.488 | 34.344 | 30.14 | 28.942 | 47.99 | 45.616 | 42.792 | 30.057 |
| Operating Income
| 50.501 | -51.976 | -56.888 | -53.076 | -10.442 | -51.42 | -50.454 | -33.127 | 3.173 | -7.517 | -7.309 | -31.155 | -27.213 | -8.711 | -46.591 | -45.591 | -31.127 | -28.639 |
| Operating Income Ratio
| 0.489 | -6.955 | 35.666 | -3.537 | -0.139 | -1.624 | -2.199 | -1.741 | 0.734 | -2.901 | -5.541 | -8.806 | -8.335 | -0.423 | -28.357 | -949.813 | -3.374 | -36.67 |
| Total Other Income Expenses Net
| 4.32 | -18.64 | 2.171 | -14.38 | -7.952 | -2.444 | -0.821 | -0.067 | 26.865 | -0.015 | 1.549 | -0.136 | -0.318 | -2.872 | 72.447 | 0.814 | 5.012 | 1.199 |
| Income Before Tax
| 54.821 | -70.616 | -54.717 | -67.456 | -18.394 | -53.864 | -51.275 | -33.194 | 2.934 | -7.532 | -5.76 | -31.291 | -27.531 | -11.583 | 25.856 | -44.777 | -28.554 | -28.077 |
| Income Before Tax Ratio
| 0.53 | -9.449 | 34.305 | -4.495 | -0.244 | -1.701 | -2.235 | -1.744 | 0.679 | -2.907 | -4.367 | -8.844 | -8.432 | -0.562 | 15.737 | -932.854 | -3.095 | -35.95 |
| Income Tax Expense
| 0.039 | 0.46 | 0.809 | 0.203 | 0.579 | 0.322 | 0.257 | 2.221 | -3.015 | 0.002 | -0.005 | 0.157 | 0.307 | -0.327 | -0.067 | -0.121 | -0.683 | 0.181 |
| Net Income
| 54.782 | -71.076 | -55.526 | -67.659 | -18.973 | -54.186 | -51.532 | -35.415 | 5.949 | -7.534 | -5.755 | -31.448 | -27.838 | -11.256 | 25.923 | -44.656 | -27.871 | -28.258 |
| Net Income Ratio
| 0.53 | -9.511 | 34.813 | -4.508 | -0.252 | -1.712 | -2.246 | -1.861 | 1.377 | -2.908 | -4.363 | -8.889 | -8.526 | -0.546 | 15.778 | -930.333 | -3.021 | -36.182 |
| EPS
| 4.91 | -11.67 | -16.25 | -50.81 | -17.26 | -78.63 | -82.19 | -56.5 | 11.1 | -16.02 | -15.52 | -85.53 | -75.95 | -30.76 | -73.1 | -141.1 | -89.89 | -144.41 |
| EPS Diluted
| 4.91 | -11.67 | -16.25 | -50.81 | -17.26 | -78.63 | -82.19 | -56.45 | 10.8 | -16.02 | -15.52 | -85.53 | -75.95 | -30.76 | -73.1 | -141.1 | -89.89 | -144.41 |
| EBITDA
| 53.541 | -42.493 | -43.226 | -53.92 | -7.128 | -48.21 | -46.59 | -29.915 | -23.037 | -7.45 | -5.141 | -11.094 | -22.689 | -2.049 | 30.757 | -39.072 | -30.026 | -27.619 |
| EBITDA Ratio
| 0.518 | -5.686 | 27.101 | -3.593 | -0.095 | -1.523 | -2.031 | -1.572 | -5.331 | -2.875 | -3.898 | -3.136 | -6.949 | -0.099 | 18.72 | -814 | -3.254 | -35.364 |